Gene Editing

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Stock Rallies on Technical Breakout Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the day finviz.com.

20 October 2025

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1

19 October 2025

Biotechnology · Gene Editing · Healthcare Innovation · Investment Analysis · NASDAQ:CRSP · Stock Market

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021

9 October 2025

Biotechnology · Gene Editing · Investment Analysis · NASDAQ:NTLA · Pharma News · Stock Market

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Quick Facts (as of 8 Oct 2025) Recent Performance and News Phase 1 data fuels rally Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin

8 October 2025

Biotechnology · Company Analysis · Gene Editing · Investment Opportunities · Stocks

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and

8 October 2025

Biotechnology · Gene Editing · Investment Analysis · Market Trends · Stocks

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of

8 October 2025

Biotechnology · Gene Editing · Investment Analysis · Pharmaceutical News · Stock Market

Biting Back: How CRISPR-Edited Mice Could Stop the Lyme Disease Plague

Lyme Disease on the Rise – And Why Mice Matter Lyme disease is often called a “plague” on Nantucket. The tiny Massachusetts island, famed for its beaches, has one of the nation’s

23 September 2025

Biotechnology · Disease Prevention · Genetics · Public Health · Science News

CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

Breaking the Genetic “Spell” of a Liver Disease Phenylketonuria (PKU) is a hereditary metabolic liver disorder where a single DNA typo disrupts the PAH enzyme that breaks down phenylalanine, an amino acid

15 September 2025

Breakthroughs · CRISPR · Genetics · Health · Medical Research

From a Gene-Edited Baby to Uranus’ Hidden Moon: August 2025’s Biggest Science Breakthroughs

August 2025 was packed with scientific advances across health, space, physics, AI, environment, energy, biology, chemistry, and technology. Below we round up the most significant global science news of the month, with

21 August 2025

Astronomy · Breakthroughs · Genetics · Science News · Technology